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Summary Two forms of reperfusion injury can occur in patients with ST-segment elevation
acute myocardial infarction who are undergoing primary angioplasty: no-reﬂow phenomenon
and reperfusion syndrome. No-reﬂow, deﬁned as low or no distal perfusion despite removal
of epicardial occlusion, can be detected by angiographic ﬂow, myocardial blush grade and
contrast echocardiography. Reperfusion syndrome involves haemodynamic and rhythmic dis-
turbances, but an overall paradoxical ST-segment increase. A variety of mechanisms give rise
to no-reﬂow, including distal embolization, leucocyte plugging and vasoconstriction. Reperfu-
sion syndrome reﬂects, at least in part, the cardiomyocyte component of reperfusion injury.
Reperfusion injury can be predicted from the initial electrocardiogram, especially when QRS
complex distortion is observed. Pharmacological prevention of reperfusion injury has been
tested in a number of trials; the most useful drugs available currently are glycoprotein
IIb/IIIa receptor blockers and adenosine. Thrombus aspiration leads to faster and greater ST-
segment resolution. Postconditioning (also called staccato reperfusion) is a new strategy that
has produced highly encouraging results, although it has been tested only in a small ran-
domized study. New tools are required to enable thrombus aspiration and postconditioning
to be carried out simultaneously. Pharmacological postconditioning can be anticipated in the
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near future, as many drugs appear to achieve the same positive effect as mechanical modiﬁed
reperfusion.
© 2008 Elsevier Masson SAS. All rights reserved.
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Résumé Les lesions de reperfusion au cours de l’infarctus du myocarde aigu traité par
angioplastie primaire se présentent sous deux aspects : le no-reﬂow et le syndrome de reper-
fusion. Le no-reﬂow se déﬁnit comme l’absence ou le ralentissement du ﬂux distal alors
que l’obstacle épicardique a été levé. Le syndrome de reperfusion associe des modiﬁcations
hémodynamiques et rythmiques mais est surtout marqué par une majoration paradoxale du
sus-décalage de ST. Le no-reﬂow est détecté notamment par angiographie conventionnelle
ou par échographie de contraste. Il est dû à un ensemble de mécanismes (embolies dis-
tales, agrégats leucocytaires, vasoconstriction, etc.). Le syndrome de reperfusion exprime
au moins en partie la composante cardiomyocytaire des lésions de reperfusion. La survenue
de ces lésions peut être prédite à partir de l’électrocardiogramme initial et notamment
en présence d’un aspect de distorsion de QRS. De nombreux essais de prévention pharma-
cologiques ont été réalisés. Les molécules les plus efﬁcaces et dès à présent utilisables sont
les antiglycoprotéines IIb/IIIa et l’adénosine. L’aspiration du thrombus permet une régres-
sion plus rapide et plus importante du sus-décalage de ST. Le postconditionnement mécanique
appelé également reperfusion « staccato » s’est montré efﬁcace dans une première petite étude
randomisée mais permet de réels espoirs. Pour combiner l’aspiration du thrombus et le post-
conditionnement simultanément de nouveaux outils sont nécessaires. Par ailleurs l’espoir de
pouvoir mettre en œuvre un postconditionnement pharmacologique dans un proche futur est
. All
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bbreviations
TP Adenosine triphosphate
CG Electrocardiogram
MR Index of microvascular resistance
VF Left ventricular function
BG Myocardial blush grade
CE Myocardial contrast echocardiography
TP Mitochondrial transition pore
R No-reﬂow
PCI Primary percutaneous coronary intervention
VF Peak volume ﬂow
ISK Reperfusion injury salvage kinase
OS Reactive oxygen species
FC Thrombolysis in myocardial infarction frame count
IMI Thrombolysis in myocardial infarction
ackground
xperimental data have shown that the ﬁnal myocardial out-
ome of an ‘ischemic—reperfusion’ sequence depends not
nly on the time delay between occlusion and reperfusion
ut also on whether lethal reperfusion injury occurs (see
art I).
Despite the early description of reperfusion syndrome
1—3] and stunned myocardium phenomenon [4], for many
ears interventional cardiologists failed to acknowledge the
oncept of lethal reperfusion injury and the reality of its
xistence in humans. The occurrence of no-reﬂow (NR) dur-
ng primary percutaneous coronary intervention (pPCI) for
T-segment elevation myocardial infarction (STEMI) was ﬁrst
a
m
t
f
trights reserved.
escribed by Krug et al. in 1966 [5], and later by Kloner
t al. in 1974 [6], in ischaemia—reperfusion experimental
nimal models in which coronary occlusion was achieved
y ligature without any thrombotic material. Nevertheless,
nterventional cardiologists continued to regard NR as a
echnical failure caused by thrombus fragmentation and dis-
al embolism [7,8].
The ﬁrst positive report of pharmacologically modiﬁed
eperfusion (using perﬂuorochemicals) failed to catch the
ttention of interventional cardiologists [9], as did the sur-
rising results of the Primary Angioplasty in Myocardial
nfarction (PAMI) stent study, in which stented patients had
slightly poorer clinical outcome [10]. The failure of, and
nconvincing results from, numerous drug trials [11] rein-
orced the belief that the principal problem during pPCI
as vascular, requiring embolism and spasm prevention [12].
owever, the ﬁrst randomized study into postconditioning in
umans [13] altered the opinion of interventional cardiolo-
ists, who started to accept that a useful link might be made
etween laboratory research and reperfusion in humans, and
hat modiﬁed reperfusion might have a role in the catheter-
zation laboratory (cath lab). The aim of this review is to
emonstrate how experimental modiﬁed reperfusion might
nﬂuence routine pPCI practice in humans.
In an attempt to clarify this complex phenomenon, it is
seful to separate the two facets of reperfusion injury — one
nvolving the endothelium and hence postreperfusion ﬂow,
nd the other involving cardiomyocytes (Fig. 1). Neverthe-
ess, these two consequences of the sudden reopening of the
rtery are closely interconnected and therapeutic options
ust target them both. Reopening of the artery is essential
o save the myocardium; prevention and treatment of reper-
usion injury is the next challenge in the quest to optimize
he ﬁnal outcome.
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Santoro et al. found that the ST-segment decreased by
more than 50% in 77% of patients with reﬂow compared
with by 10% in patients with echo NR [26]. Combining MBG
and ST-segment resolution makes it possible to predict early
and late left ventricular function (LVF) recovery [27]. The
combination of MBG 2 or 3 with an ST-segment decrease of
more than 50% has been shown to produce seven-day and
six-month LVF recovery rates of 65 and 95%, respectively.
By comparison, MBG 2 or 3 and an ST-segment decrease
of less than 50% resulted in seven-day and six-month LVF
recovery rates of 24 and 86%, respectively. In patients with
neither MBG 2 or 3, nor an ST-segment decrease, the seven-
day and six-month LVF recovery rates were 18 and 32%,
respectively.
It may be possible to detect NR ‘on-line’ using a new
measure — the index of microvascular resistance (IMR) [28].
Using a pressure sensor wire (as for fractional ﬂow measure-
ment), after injection of adenosine, an IMR greater than 32
units was predictive of poor LVF recovery at three-month
follow-up.
NR can also be assessed by intracoronary Doppler ﬂow,
with average peak velocity and early systolic retrograde ﬂow
correlating well with MCE defect [29], and by magnetic reso-
nance imaging [30—33]. Positron tomography, like magnetic
resonance imaging, is a technique that will be developed in
the future [34], especially for therapeutic trials. Feldman et
al. found a good correlation between coronary ﬂow reserve
immediately after pPCI and ST-segment recovery [35]. The
criteria deﬁning NR, depending on the assessment technique
used, are summarized in Fig. 2.
ST-segment decrease is probably linked to NR, but also
depends on cardiomyocyte damage. By pooling the results
of two studies comparing MBG and ST-segment resolution
[18,27], it is possible to identify four different proﬁles
after pPCI (Fig. 3), providing conﬁrmation that endothe-
lial and cardiomyocyte responses to reperfusion do not
always evolve in parallel. The four different proﬁles are as
follows:
• ﬂow recovery with ST-segment resolution;
• ﬂow recovery without ST-segment resolution;
• low-reﬂow or NR without ST-segment resolution;Figure 1. The two facets of reperfusion injury, involving endothe-
lium and cardiomyocytes.
The no-reﬂow phenomenon
First reported 20 years ago after thrombolytic therapy using
scintigraphy [14], and again one year later using angiography
[15], NR is deﬁned as the absence of or poor myocar-
dial perfusion despite the removal of the epicardic artery
obstruction. Numerous techniques can be used to assess this
problem. A ﬁnal Thrombolysis In Myocardial Infarction (TIMI)
of grade less than 3 ﬂow is seen with angiography, extend-
ing from no-ﬂow to slow-ﬂow, despite the occlusion having
been removed with no residual obstacle or vessel dissection
[7,16]. The incidence of NR, judged on the basis of the initial
TIMI classiﬁcation, is around 10—15%. The effective myocar-
dial perfusion can be measured more accurately using the
TIMI frame count (TFC) [17], which is deﬁned as the num-
ber of frames required for dye to reach the distal artery;
NR is considered when the TFC is greater than 40 frames
[17].
The gold standard measure of myocardial reperfusion is
myocardial blush grade (MBG) [18]: MBG 0 is deﬁned as
no myocardial opaciﬁcation; MBG 1 as myocardial opaci-
ﬁcation without any dye clearance; MBG 2 as myocardial
opaciﬁcation with slow clearance; and MBG 3 as myocar-
dial opaciﬁcation with quick clearance. Only 21% of patients
who reached TIMI grade 3 ﬂow after pPCI had MBG 3.
Using conventional angiographic TIMI grade ﬂow assessment,
Anderson et al. showed that only TIMI grade 3 ﬂow could
be considered to be an indicator of successful reperfusion
[19]. MBG is the most powerful predictor of prognosis [20].
Going from MBG 0 to 3, 30-day mortality has been shown
to decrease from 6.2 to 5.1%, 4.4 and 2.0%, respectively, in
patients with heart failure at presentation [21], with MBG 0
and 1 associated with the worst 400-day follow-up prognosis
[21]. Taken together, these data encourage interventional
cardiologists not only to achieve but also to go beyond TIMI
grade 3 ﬂow [22].
Myocardial contrast echocardiography (MCE) has shown
NR to be present in patients even if they have reached angio-
graphic TIMI grade 3 ﬂow; NR was observed in 16—40% of such
patients and in 100% of those with TIMI grade 2 ﬂow [23].
Prognosis is linked directly to MCE reﬂow [24]. Galiuto et al.
found that even in patients with TIMI grade 3 ﬂow, a contrast
defect greater than 25% was the most accurate predictor of
left ventricular remodelling — better than MBG or ST — seg-
ment resolution [25]. The degree of contrast defect is linked
closely to ST-segment decrease.
Figure 2. Deﬁnition of NR according to assessment technique
used.
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Figure 3. Discrepancies between angiographic NR deﬁnition and
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ut not always (2) predictive of ST-segment resolution, and vice
ersa (3,4).
ST-segment recovery despite low-reﬂow or NR. These
conﬂicting characteristics highlight the two facets of
reperfusion injury — endothelial and myocardial.
The time course of NR must be taken into account. Stud-
es in animals have shown that even after early hyperaemia
36] there is a progressive loss of infarct perfusion [36—38].
wenty years ago, Ambrosio et al. found that after two
inutes of reperfusion in a dog model, the area of impaired
eperfusion averaged 9.5± 3.0%, whereas it was three times
s large after 3.5 h of reperfusion (25.9± 8.2%) [36]. Few
tudies have been done in humans to address this evolutive
spect of NR. Tsunoda et al. observed two different groups
ho had reached angiographic TIMI grade 3 ﬂow [39]. One
roup experienced an early decrease in average peak veloc-
ty followed by a late recovery, while the other experienced
continuous decrease in average peak velocity; the late
ecovery group showed a greater improvement in LVF.
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igure 4. Paradoxical ST-segment increase at reperfusion in acute ante
PCI: (1) initial ECG with QRS distortion (grade 3); (2) immediately postr
low and delayed ST-segment recovery.J.-P. Monassier
It is now evident that the different tools that can
e used to assess the efﬁcacy of myocardial reperfusion
fter pPCI show that NR exists in a large number of
atients who have a good immediate angiographic result.
lassic TIMI grade 3 ﬂow is required, but is not sufﬁ-
iently accurate to distinguish between distal reﬂow and
R.
The mechanisms of NR are well elucidated, and include
istal embolism, leucocyte and platelet plugging, microvas-
ular spasm, capillary swelling and external compression by
ypercontracted cardiomyocytes [34]. A variety of clinical
nd biological variables may predict the occurrence of NR;
hese include initial hyperglycaemia [40—42], high leucocyte
ount [43], troponin elevation at presentation [44], longer
ime delay, anterior infarcts [45] and lack of preinfarction
ngina [46].
ardiomyocyte reperfusion injury
hile interventional cardiologists have paid heed to the
ngiographic results of pPCI, less focus has been placed on
he deleterious effects of reperfusion on cardiomyocytes.
tunned myocardium [4] has long been considered to be a
eﬂection of the time needed to repair ischaemic damage
ather than a consequence of reperfusion injury.
Reperfusion syndrome [3] combines cardiac arrhythmias
uch as accelerated idioventricular rhythm, severe brady-
ardia, arterial pressure drop leading in rare cases to
lectromechanical dissociation [2], chest pain paroxysm
nd ST-segment elevation increase [1] (Fig. 4). ST-segment
onitoring during and immediately after culprit artery des-
bstruction might provide useful information about the
rior ST-segment elevation acute myocardial infarction treated with
eﬂow ECG with sudden major increase in ST-segment elevation; (3)
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myocardial response to reoxygenation. An increase in ST-
segment shift may be caused by ionic cellular mechanisms
such as potassium efﬂux (see Part I). A paradoxical increase
in chest pain and ST-segment elevation can occur immedi-
ately after the reopening of the artery or a few minutes
later [1]. The fact that even with MBG 3, the ST-segment
does not improve in around 15% of patients, supports the
existence of two facets of reperfusion injury — vascular and
cellular [18]. Santoro et al. tried to differentiate between
NR and cardiomyocyte reperfusion injury [26]. Eleven of 37
patients (29.7%) treated with pPCI experienced MCE NR. A
sudden postreperfusion ST-segment increase of more than
30% occurred in 10 patients (27.0%), including three of 26
(11.5%) with MCE reﬂow compared with seven of 11 (63.6%)
with MCE NR, which shows that cellular mechanisms can
cause the ST-segment to deteriorate even in the presence
of reﬂow. Nevertheless, the additional ST-segment increase
was of shorter duration in the reﬂow group than in the NR
group.
Thus, the components of reperfusion injury are clearly
interwoven and angiographic reﬂow must be combined with
immediate ST-segment shift after pPCI (Fig. 2) [47].Initial electrocardiogram and reperfusion
injury
The initial electrocardiogram (ECG) is a reliable predictor
of ST-segment and angiographic outcome after pPCI. The
d
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Figure 5. Early (day of hospitalization) anterior infarct: progressive ev
grade 3 with distortion (initial ECG in cath lab), to (3) sudden increase
coronary care unit.cath lab 569
reater the sum of ST-segment elevation in acute anterior
nfarctions, the worse the ventricular prognosis as a result
f severe ischaemia and reperfusion injury [48,49]. Kurisu
t al. found a sum of ST-segment elevation greater than
0mm to be an appropriate cut-off value [49]. Patients
ith less severe ST-segment elevation presented more fre-
uently with prodromal angina and may therefore have been
rotected by preconditioning [49]. Greater ST-segment ele-
ation in the D1 lead than in the aVL lead is associated
ith impaired myocardial reperfusion (assessed by MBG) and
ess myocardial salvage in patients with recanalized ante-
ior infarctions [50], as well as with ST-segment depression
n the aVR lead in patients with acute inferior infarctions
51]. In patients with inferior infarctions, a larger sum of ST-
egment depression in the V4—V6 leads than in the V1—V4
eads is also considered to be a marker of poor prognosis,
lthough a clear relationship with reperfusion injury has not
een established [52].
The most studied feature of the initial ECG is QRS com-
lex distortion [52—54]. The initial ECG can be categorized
s follows on the basis of repolarization: grade I, T-wave
eaking; grade II, ST-segment elevation without distortion of
he terminal portion of QRS complex; grade III, ST-segment
levation with distortion of the QRS complex, deﬁned as
isappearance of the S wave in the VI—V3 leads or appear-
nce of ST-segment elevation (measured at the J point)
reater than 50% of the R wave in the same lead (Fig. 5).
grade III ECG can be observed in around 30% of patients
52] and predicts a poorer prognosis despite infarct-related
olution from (1) initial grade 1 ECG (prehospital recording), to (2)
in ST-segment after pPCI and (4) slow recovery one hour later in
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rtery reopening, due to more frequent NR and less fre-
uent ST-segment decrease as a consequence of reperfusion
njury.
It is clear, therefore, that admission ECG and ST-segment
hanges after pPCI may be valuable predictors and markers
f global reperfusion injury. Immediate ST-segment changes
fter pPCI can be used reliably to unmask reperfusion injury,
hich in turn enables appropriate modiﬁcations to be made
o the reperfusion strategy; given the association of reper-
usion injury with mortality rate and ﬁnal LVF, this measure
ay emerge as a strong surrogate endpoint in future clinical
rials.
herapeutic options
nexpected failures
ollowing robust experimental results, a variety of
olecules have been tested for their ability to counter-
ct either NR or cardiomyocyte reperfusion injury; of these,
eactive oxygen species (ROS) scavengers [55], inhibitors of
he sodium-hydrogen exchanger [56] and inhibitors of the
nﬂammatory cascade [57—59] have failed to produce sig-
iﬁcant beneﬁts. The reasons for these surprisingly negative
esults cannot be discussed in detail here and for each type
f molecule, but may include the multifactorial mechanisms
f reperfusion injury and the need for these mechanisms to
e acted upon simultaneously, the intravenous mode of drug
elivery, the timing of delivery (during ischaemia or during
eperfusion), the gap between the experimental setting and
TEMI in humans, and the low risk level of patients included
n the studies.
The therapeutic options discussed below have all pro-
uced some positive results and are either available for
mmediate use or are under development for future use.
hrombectomy and ﬁlter devices
iven that distal embolization is one of the causes of NR
60], various devices have been proposed for use in the
emoval of thrombi or the prevention of distal embolisms
nto arterioles and small coronary branches. Numerous small
rials have demonstrated the efﬁcacy of these devices in
erms of improved ﬂow and ST-segment regression; MBG
can be reached in around 85% of patients compared
ith 45% after conventional pPCI, and immediate complete
T-segment regression is noted in around 70% of patients
ompared with 50% after conventional pPCI [12,61—63].
evertheless, in a meta-analysis of 14 trials, antiembolic
ools had no effect on major clinical endpoints (deaths and
einfarction) [64]. This ﬁnding does not mean that these
evices are not useful, but is a reﬂection of the fact that dis-
al embolisms are only one component of reperfusion injury
nd NR. Furthermore, in each of these trials, the death rate
as too low to enable an effect on mortality to be assessed.
The extent of ST-segment resolution is a strong predictorf mean and long-term prognosis [65], and positive results
sing this criterion as a surrogate endpoint may be indicative
f a beneﬁcial impact of thrombectomy devices on long-
erm clinical events. Account must also now be taken of
recent randomized trial that included more than 1000
t
w
i
(J.-P. Monassier
atients and compared thrombectomy with stenting alone;
he thrombectomy group had a signiﬁcantly better MBG,
ore frequent complete ST-segment resolution and a lower
eath rate [66]. Thus, thrombectomy devices have an impor-
ant role to play, especially in patients with high thrombus
urden [67], although they are probably unable to achieve
he therapeutic goal when used in isolation.
lycoprotein IIb/IIIa receptor blockade
bciximab has been tested widely and positively as an
djunctive therapy before and during pPCI; its efﬁcacy is
ue to an antithrombotic effect, preventing subacute stent
hrombosis, but is also attributable to an improvement in
istal ﬂow. This non-speciﬁc drug interacts not only with
latelets (decreasing platelet reactivity, aggregates, plug-
ing and embolization) but also inhibits platelet—leucocyte
nteraction and hence the cytotoxic inﬂammatory response
68—71]. Abciximab is even more effective when initial
latelet volume is greater than 10.3 ﬂ [72]. Hence abcix-
mab, due to its non-speciﬁc action on platelets and
eucocytes, is a logical adjunct to pPCI. Neumann et al.
howed an improvement in peak volume ﬂow (PVF) in
TEMI patients treated with pPCI, stents and abciximab
68]; PVF averaged 18.1 cm/s (13.6—22.6) compared with
0.4 cm/s (5.4—15.4) in patients who did not receive abcix-
mab (p = 0.024). A similar decrease in the incidence of NR
ith abciximab was observed when evaluating microvascular
ermeability with contrast echocardiography [69].
denosine
denosine is an endogenous nucleoside produced by the
egradation of adenosine triphosphate (ATP) [73]. In a nor-
al physiological setting it is present in a 40-fold greater
oncentration in endothelial cells, whereas myocytes
ecome the major source of adenosine during ischaemia due
o the inability of mitochondria to rephosphorylate adeno-
ine diphosphate and adenosine monophosphate. Adenosine
s a ubiquitous molecule that promotes a variety of
etabolic effects; it acts on all the reperfusion injury mech-
nisms (with the exception of distal embolism), promoting
reservation of microvascular ﬂow, inhibiting neutrophils
nd the inﬂammatory cascade, reducing ROS synthesis and
tabilizing cellular membranes, restoring calcium homeosta-
is and mediating postconditioning (see below) [73]. Marzilli
t al. showed that the intracoronary injection of adenosine
efore reperfusion (using a small perfusion balloon settled
istally) prevents NR [74]. In a randomized study involving
4 patients, NR occurred in only one patient (3.7%) who
eceived adenosine compared with 25.9% of patients in the
ontrol group (p = 0.04).
Three large, randomized trials of adenosine have been
eported. The Acute Myocardial Infarction Study of Adeno-
ine (AMISTAD) was performed in 236 patients with anterior
nd inferior infarctions [75]. Patients received thrombolytic
herapy plus adenosine 70g/kg per min or placebo for
hree hours. At day 6 an isotopic reduction in infarct size
as seen in the adenosine group; the reduction was greatest
n patients with an anterior infarct.
The Attenuation by Adenosine of Cardiac Complications
ATTACC) study was a prospective, large-scale, random-
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ized, placebo-controlled study using a low adenosine dose
(10g/kg per min) infused intravenously for six hours in
patients undergoing thrombolysis [76]. At the six-month
follow-up of 292 patients with anterior infarcts, the adeno-
sine group showed a trend for less all-cause mortality (8.4%
versus 15.3%; p = 0.07) and cardiovascular mortality (8.4%
versus 14.6%; p = 0.08). Furthermore, in a post hoc analysis
of a subgroup with anterior infarcts and severely depressed
LVF, the six-month death rate was signiﬁcantly lower in the
adenosine group (2.0% versus 12.1%; p = 0.007).
Finally, the Acute Myocardial Infarction Study of Adeno-
sine II (AMISTAD-II) was a double-blind, placebo-controlled,
randomized study in 2118 patients with anterior STEMI
undergoing thrombolysis or pPCI [77,78]. Two doses of
adenosine were tested: 50 and 70g/kg per min. Despite
the lack of difference between the two groups in terms of
major clinical endpoints, a marked reduction in infarct size
was observed in the high-dose group. In a post hoc anal-
ysis, among patients receiving reperfusion therapy within
three hours of symptoms, adenosine reduced one-month
and six-month mortality rates signiﬁcantly: 5.2% versus 9.2%
(p = 0.014) and 7.3% versus 11.2% (p = 0.03), respectively
[78]. Adenosine can be considered to be an effective adjunc-
tive therapy that minimizes infarct size and clinical events
in patients with anterior infarcts treated with reperfusion
therapy within 3—4h of chest pain onset.
Nicorandil
Nicorandil is another molecule that has the potential to
limit reperfusion injury [79]; this hybrid of an ATP-sensitive
potassium-channel activator and a nitrate contributes to
the reduction in preload and afterload, works as an ROS
scavenger, and has neutrophil-modulating properties. The
opening of potassium-ATP channels is known to be involved
in preconditioning and postconditioning (see Part I). In two
randomized studies, patients undergoing pPCI received nico-
randil by intravenous infusion (4mg bolus plus 6mg/h for six
hours) [80], or by a combination of intracoronary admin-
istration (1—2mg) and intravenous administration (4mg
bolus plus 6mg/h for 16 h) [81]; in both studies, patients
who received nicorandil had a better ﬁnal ﬂow, a greater
ST-segment resolution and fewer major clinical events,
including deaths. The strategy of combining intracoronary
and intravenous drug administration appears to be the most
effective.
Postconditioning or modiﬁed reperfusion
Jakob Vinten-Johansen’s group (Atlanta, USA) has probably
launched a new era in the treatment of reperfusion injury
and the protection of ischaemic but viable myocardium
(see Part I). This group has demonstrated that gradual and
haemodynamically controlled reperfusion is more effective
than abrupt ‘off-on’ artery reopening, and has transformed
preconditioning from a random phenomenon to a feasible
therapeutic strategy that may become established as a sec-
ond stage in STEMI reperfusion treatment.
Postconditioning reduces infarct size, preserves vas-
cular endothelial function, decreases polymorphonuclear
neutrophil accumulation and activation, decreases calcium
overload, delays the restoration of neutral pH, reduces
d
i
t
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poptosis, inhibits ROS production and decreases cellular
edema. Hence, mechanical manipulation of the early phase
f reperfusion can reduce post-ischaemic endothelial and
yocardial injury, while providing conclusive proof of the
xistence of reperfusion injury. The ﬁrst randomized clin-
cal study showed that postconditioning during pPCI saved
2% of enzyme release, and turned a laboratory curiosity
nto a successful clinical application [13].
Proposals for the mechanisms underlying the efﬁcacy of
ostconditioning have come from molecular biology stud-
es. Yellon’s group has shown that it is possible to protect
eperfused myocardium by activating the prosurvival kinase
ignalling pathway, now called the reperfusion injury sal-
age kinase (RISK) pathway (see Part I). The effectors of
hese salvage kinases are the recently discovered mitochon-
rial transition pores (MTPs) and potassium—ATP channels.
hen opened (an effect promoted by calcium overload,
xidative stress and ATP depletion), MTPs lose their mito-
hondrial protective role, causing mitochondria to undergo
assive swelling, and to become uncoupled and unable to
aintain pH gradient and membrane potential; instead of
roducing ATP they start to degrade residual ATP. A sec-
nd consequence of mitochondrial swelling is mitochondrial
nner membrane architectural changes that result in the
elease of cytochrome c, which in turn activates proapop-
otic caspases. The ﬁrst postconditioning mechanism seems
o prevent MTP opening and to preserve mitochondrial func-
ion. The second effector of postconditioning may be the
pening of mitochondrial potassium—ATP channels, provok-
ng a partial mitochondrial membrane depolarization and
reventing calcium overload. The opening of potassium—ATP
hannels in sarcoplasmic reticulum may also decrease cal-
ium overload and hence prevent myoﬁbrillar contracture.
Not all of the signalling molecules that induce salvage
athways are known, although adenosine is recognized as
eing one of these triggers. The postconditioning technique
ay slow down adenosine washout by ‘ramped’ reperfu-
ion. Bradykinin, which is synthesized during ischaemia, may
lso initiate salvage mechanisms. Other drugs that mimic
ostconditioning, such as opioids, insulin, cyclosporin A,
ngiotensin inhibitors, glucagon-like peptide-1, erythropoi-
tin, statins, cardiotrophin-1, protein kinase C and trans-
orming growth factor beta-1, may also activate these path-
ays and/or inhibit apoptosis directly by blocking caspases
82]. Some of these drugs (cyclosporin A, insulin and opioids)
ay be in clinical use in this setting in the near future.
inimalist and low pressure reperfusion
novel strategy has been proposed recently, based on
he hypothesis that achieving a TIMI grade 3 ﬂow (hav-
ng crossed the occlusion with the wire or a small
alloon, but leaving the stenosis), postponing the implan-
ation of a stent for 12—24 h and preventing reocclusion
ith strong antithrombotic treatment, might protect
yocardium against reperfusion injury [83]. Such a scheme
esults in low distal pressure reperfusion, delays washout,
ecreases mechanical stretch and may mimic postcondition-
ng. Indeed, low pressure reperfusion is known to induce
he RISK pathway, suggesting that such minimalist reper-
usion might be comparable with postconditioning. In a
ilot, non-randomized study of minimalist reperfusion, ST-
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Rigure 6. PCI tools available for the prevention and treatment of
nfusion; (2 + 3) thrombus aspiration and occlusive balloon catheter
hrombus aspiration and perfusion catheter without balloon (5,6).
egment resolution (> 50%) at 60min was achieved in 84% of
atients [83].
ractical issues
aving convinced interventional cardiologists that the use of
n ‘off-on’ pPCI technique can kill many viable endothelial
nd cardiomyocytes cells, how can we now transform exper-
mental and preliminary clinical data into a viable modiﬁed
eperfusion technique for clinical use? Two concepts must
e taken into consideration: ﬁrstly, that the time window
or reperfusion injury prevention starts at the ﬁrst minute
f reperfusion but extends over the next few hours (see Part
); secondly, that thrombus removal and postconditioning are
ounteractive — starting desobstruction with thrombus aspi-
ation causes abrupt myocardial reﬂow, while starting with
echanical postconditioning can induce thrombus migra-
ion.
Pharmacological strategies must therefore be used with
PCI, including glycoprotein IIb/IIIa receptor blockade and
ossibly high-dose adenosine, and new drugs may be devel-
ped for this purpose in the near future. In addition,
oth thrombus aspiration and mechanical postcondition-
ng may be integrated into the pPCI procedure; under
hese circumstances, new tools will have to be developed
nd tested to ensure that distal embolizations are pre-
ented and that salvage pathways are induced (Fig. 6)
66].
a
t
m
o
a
arfusion injury: (1) coaxial perfusion balloon catheter allowing drug
itting simultaneous thrombus aspiration and postconditioning; (4)
nresolved issues and future options
urrent data demonstrate that while there is no unique
magic bullet’ for preventing reperfusion injury, a vari-
ty of therapeutic options do exist. If postconditioning is
dopted as the principal strategy it will be necessary to
dentify the optimal sequences for balloon inﬂations and
eﬂations (length and number), as differences can exist
etween animal models and humans. The question remains
s to whether the postconditioning technique must be driven
y ST-segment monitoring and prolonged until a signiﬁcant
ecrease in ST-segment elevation is achieved.
In the future, pharmacological postconditioning may be
dopted via the intravenous route or intracoronary injec-
ion. Intravenous pharmacological postconditioning may also
e beneﬁcial for patients treated with thrombolytic therapy.
inally, pharmacological reperfusion injury treatment must
e continued for a number of hours to counteract the second
elayed window for reperfusion injury.
onclusion
eperfusion injury is a proven event, occurring immediately
fter coronary reopening in STEMI patients but enduring
hereafter. Prevention of reperfusion injury might optimize
yocardial salvage, acting on the vascular bed as well as
n cardiomyocytes. Glycoprotein IIb/IIIa receptor blockers
nd adenosine are two pharmacological treatments that
re applicable immediately, as are thrombus aspiration and
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mechanical modiﬁed reperfusion (postconditioning), pro-
vided that both of these strategies can be used almost simul-
taneously. More trials are needed, but a new era of myocar-
dial reperfusion is certainly starting, dedicated not only to
the epicardial artery but also to microvascular reperfusion
and cardiomyocyte salvage. On-line ST-segment monitoring,
available in every cath lab, provides an excellent means of
measuring the immediate effects of such therapies.
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